Cargando…

The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine

HCV represents a global health problem with ~200 million individuals currently infected, worldwide. With the high cost of antiviral therapies, the global burden of chronic hepatitis C infection (CHCV) infection will be substantially reduced by the development of an effective vaccine for HCV. The fie...

Descripción completa

Detalles Bibliográficos
Autor principal:	Torresi, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674006/ https://www.ncbi.nlm.nih.gov/pubmed/29163442 http://dx.doi.org/10.3389/fmicb.2017.02163

Ejemplares similares

Zika virus-like particle (VLP) based vaccine
por: Boigard, Hélène, et al.
Publicado: (2017)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Erythro-VLP: Erythrocyte Virus-Like-Particles
por: Himbert, Sebastian, et al.
Publicado: (2021)

Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic
por: López-Macías, Constantino
Publicado: (2012)

Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery
por: Christiansen, D., et al.
Publicado: (2019)

Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C
por: Masavuli, Makutiro Ghislain, et al.
Publicado: (2017)

Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
por: Klimek, Ludger, et al.
Publicado: (2018)

On the Effect of Thermodynamic Equilibrium on the Assembly Efficiency of Complex Multi-Layered Virus-Like Particles (VLP): the Case of Rotavirus VLP
por: Roldão, António, et al.
Publicado: (2012)

VLP‐factory™ and ADDomer(©): Self‐assembling Virus‐Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope Display
por: Sari‐Ak, Duygu, et al.
Publicado: (2021)

Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates
por: Collett, Simon, et al.
Publicado: (2023)

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
por: Christiansen, D., et al.
Publicado: (2018)

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus
por: Garg, Himanshu, et al.
Publicado: (2020)

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)
por: Huber, Bettina, et al.
Publicado: (2017)

Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions
por: Antanasijevic, Aleksandar, et al.
Publicado: (2016)

Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3
por: Mekonnen, Zelalem A., et al.
Publicado: (2020)

Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains
por: Chu, Ki-Back, et al.
Publicado: (2021)

A Hydrodynamic Approach to the Study of HIV Virus-Like Particle (VLP) Tangential Flow Filtration
por: Wolf, Tobias, et al.
Publicado: (2022)

The transmembrane replacement H7N9-VLP vaccine displays high levels of protection in mice
por: Qin, Jianru, et al.
Publicado: (2022)

Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
por: Zhang, Beibei, et al.
Publicado: (2023)

Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach
por: Ghorbani, A., et al.
Publicado: (2020)

Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus
por: Braz Gomes, Kimberly, et al.
Publicado: (2021)

A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system
por: Pankrac, Joshua, et al.
Publicado: (2018)

Virus-like Particle (VLP) Mediated Antigen Delivery as a Sensitization Tool of Experimental Allergy Mouse Models
por: Kim, Juhyung, et al.
Publicado: (2020)

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)
por: Dye, John M., et al.
Publicado: (2016)

Isotype-specific antibody responses to rotavirus and virus proteins in cows inoculated with subunit vaccines composed of recombinant SA11 rotavirus core-like particles (CLP) or virus-like particles (VLP)
por: Fernandez, F.M., et al.
Publicado: (1996)

LB18. An Enveloped Virus-like Particle (eVLP) Cytomegalovirus (CMV) Vaccine Is Immunogenic and Safe: Results of a First-in-Humans Study
por: Gantt, Soren, et al.
Publicado: (2018)

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements
por: Yu, Dong-Shan, et al.
Publicado: (2018)

Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas
por: Govan, Vandana A, et al.
Publicado: (2008)

Enhanced Immunogenicity of an Influenza Ectodomain Matrix-2 Protein Virus-like Particle (M2e VLP) Using Polymeric Microparticles for Vaccine Delivery
por: Gomes, Keegan Braz, et al.
Publicado: (2022)

2888. Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age
por: Richardson, Jason S, et al.
Publicado: (2023)

Corrigendum: Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements
por: Yu, Dong-Shan, et al.
Publicado: (2020)

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus
por: Mobini, Saeed, et al.
Publicado: (2020)

RNA Phage VLP-Based Vaccine Platforms
por: Peabody, David S., et al.
Publicado: (2021)

Genome-Wide Search for Competing Endogenous RNAs Responsible for the Effects Induced by Ebola Virus Replication and Transcription Using a trVLP System
por: Wang, Zhong-Yi, et al.
Publicado: (2017)

Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines
por: Fernandez, F.M., et al.
Publicado: (1998)

Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming
por: Viscidi, Raphael P., et al.
Publicado: (2023)

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
por: Tariq, Hasnat, et al.
Publicado: (2022)

Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine
por: Kumar, Kiven, et al.
Publicado: (2023)

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2017)

2276. Immunogenicity of Takeda’s Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age
por: Masuda, Taisei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8j7ohi9slmmnr2gbkhkggbqqj2